GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Other Operating Expense

Cantargia AB (OSTO:CANTA) Other Operating Expense : kr-2.71 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Other Operating Expense?

Cantargia AB's Other Operating Expense for the three months ended in Sep. 2024 was kr-0.39 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was kr-2.71 Mil.

Cantargia AB's quarterly Other Operating Expense declined from Mar. 2024 (kr0.44 Mil) to Jun. 2024 (kr-0.09 Mil) and declined from Jun. 2024 (kr-0.09 Mil) to Sep. 2024 (kr-0.39 Mil).

Cantargia AB's annual Other Operating Expense increased from Dec. 2021 (kr-0.00 Mil) to Dec. 2022 (kr-0.00 Mil) but then declined from Dec. 2022 (kr-0.00 Mil) to Dec. 2023 (kr-0.00 Mil).


Cantargia AB Other Operating Expense Historical Data

The historical data trend for Cantargia AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Other Operating Expense Chart

Cantargia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cantargia AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 -2.66 0.44 -0.09 -0.39

Cantargia AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines